Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant ...

Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...

Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the ...

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult ...

Here we go again. From the New York Health Department: Anyone Who Ate Food From ilili Restaurant During January 31 – February ...

The following is a summary of “Clinical subtypes in critically ill patients with sepsis: validation and parsimonious ...